Skip To Main Content

Oncology

Browse and review clinical resources related to oncology below.

Cytokine Release Syndrome icon

Cytokine Release Syndrome (CRS) Overview

Learn more about CRS

To view a PDF of the above document, please click here.

PD-L1 icon

The PD-L1 Pathway

We are continuing to advance the understanding of cancer immunotherapy by researching pathways that can be targeted simultaneously with the PD-L1/PD-1 pathway to address various immune escape mechanisms in cancer.

PD-L1 pathway inhibition has taken an important role in helping to restore a key part of the cancer immunity cycle.1

PD-L1 pathway

Immune Escape

Tumor cells can escape the antitumor immune response in several ways

Tumor cells can evade the immune system by disrupting any of the key T-cell activities necessary to initiate and perpetuate an antitumor immune response: T-cell generation, T-cell infiltration, or tumor cell killing.1-3

Disruption of any steps of the cancer immunity cycle can ultimately result in tumor growth.2

PD-L1 cancer immunity cycle

*Tumor cell killing by CD8+ T cells.

Targeting PD-L1 simultaneously with other pathways may help restore the cancer immunity cycle

As a key immunosuppressive driver, the PD-L1 pathway is an important target that may help invigorate antitumor T-cell activity in the tumor microenvironment.1,4

PD-L1 inhibition may help restore tumor cell killing.4*

PD-L1 tumor killing

*Tumor cell killing by CD8+ T cells.

  1. In cancer, the PD-L1 ligand is expressed on tumor cells and immune cells. When bound to its receptors, PD-1 and B7.1 on T cells, PD-L1 deactivates cytotoxic T cells.

  2. PD-L1 inhibition may prevent T-cell deactivation.

  3. Reinvigorated T cells can then attack and kill tumor cells.

However, cancers may use multiple immune escape mechanisms. Targeting PD-L1 simultaneously with other pathways may be necessary to restore a fully functional cancer immunity cycle.1

We are actively researching pathway combinations with PD-L1.5

    • Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27(8):1492-1504. doi:10.1093/annonc/mdw217

      Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27(8):1492-1504. doi:10.1093/annonc/mdw217

    • Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10. doi:10.1016/j.immuni.2013.07.012

      Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10. doi:10.1016/j.immuni.2013.07.012

    • Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321-330. doi:10.1038/nature21349

      Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321-330. doi:10.1038/nature21349

    • Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580-6587. doi:10.1158/1078-0432.CCR-12-1362

      Chen DS, Irving BA, Hodi FS. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res. 2012;18(24):6580-6587. doi:10.1158/1078-0432.CCR-12-1362

    • Roche. 2021 results. Updated February 3, 2022. Accessed February 15, 2022. https://assets.cwp.roche.com/f/126832/x/baa445a513/irp220203-a.pdf

      Roche. 2021 results. Updated February 3, 2022. Accessed February 15, 2022. https://assets.cwp.roche.com/f/126832/x/baa445a513/irp220203-a.pdf